menu
    • menu
    [{"orgOrder":0,"company":"Curevo Vaccine","sponsor":"Mogam Biotechnology Research Institute | Green Cross Lab Cell","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Amezosvatein","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Curevo Vaccine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Curevo Vaccine \/ Mogam Biotechnology Research Institute | Green Cross Lab Cell","highestDevelopmentStatusID":"8","companyTruncated":"Curevo Vaccine \/ Mogam Biotechnology Research Institute | Green Cross Lab Cell"},{"orgOrder":0,"company":"Curevo Vaccine","sponsor":"Access to Advanced Health Institute | Mogam Biotechnology Research Institute | Green Cross Lab Cell","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2019","type":"Inapplicable","leadProduct":"Amezosvatein","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Curevo Vaccine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Curevo Vaccine \/ Access to Advanced Health Institute | Mogam Biotechnology Research Institute | Green Cross Lab Cell","highestDevelopmentStatusID":"8","companyTruncated":"Curevo Vaccine \/ Access to Advanced Health Institute | Mogam Biotechnology Research Institute | Green Cross Lab Cell"},{"orgOrder":0,"company":"Curevo Vaccine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"Amezosvatein","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Curevo Vaccine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Curevo Vaccine \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Curevo Vaccine \/ Undisclosed"},{"orgOrder":0,"company":"Curevo Vaccine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Amezosvatein","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Curevo Vaccine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Curevo Vaccine \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Curevo Vaccine \/ Undisclosed"},{"orgOrder":0,"company":"Curevo Vaccine","sponsor":"Janus Henderson Investors","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Series A Financing","leadProduct":"Amezosvatein","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Curevo Vaccine","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.029999999999999999,"dosageForm":"Injection","sponsorNew":"Curevo Vaccine \/ Janus Henderson Investors","highestDevelopmentStatusID":"8","companyTruncated":"Curevo Vaccine \/ Janus Henderson Investors"},{"orgOrder":0,"company":"Curevo Vaccine","sponsor":"Medicxi","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2025","type":"Series B Financing","leadProduct":"Amezosvatein","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Curevo Vaccine","amount2":0.11,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.11,"dosageForm":"Injection","sponsorNew":"Curevo Vaccine \/ Medicxi","highestDevelopmentStatusID":"8","companyTruncated":"Curevo Vaccine \/ Medicxi"},{"orgOrder":0,"company":"Curevo Vaccine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2025","type":"Inapplicable","leadProduct":"Amezosvatein","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Curevo Vaccine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Curevo Vaccine \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Curevo Vaccine \/ Undisclosed"},{"orgOrder":0,"company":"Curevo Vaccine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"Amezosvatein","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Curevo Vaccine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Curevo Vaccine \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Curevo Vaccine \/ Undisclosed"},{"orgOrder":0,"company":"Curevo Vaccine","sponsor":"GC Biopharma","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Vaccine","year":"2025","type":"Agreement","leadProduct":"Amezosvatein","moa":"TLR4","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Curevo Vaccine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Curevo Vaccine \/ Curevo Vaccine","highestDevelopmentStatusID":"8","companyTruncated":"Curevo Vaccine \/ Curevo Vaccine"}]

    Find Clinical Drug Pipeline Developments & Deals by Curevo Vaccine

    Menu

    Curevo Vaccine

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Curevo Vaccine

                            U.S.A arrow
                            Neuroscience
                            Not Confirmed

                            Curevo Vaccine

                            U.S.A arrow
                            Neuroscience
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Amezosvatein

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II

                            Recipient : GC Biopharma

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Gc Biopharma Acquires CMO Rights for Shingles Vaccine from Curevo Vaccine

                            Details : GC Biopharma will be responsible for producing a portion of the commercial supply of CRV-101 (amezosvatein), , a recombinant shingles vaccine currently under clinical development.

                            Product Name : CRV-101

                            Product Type : Vaccine

                            Upfront Cash : Undisclosed

                            October 13, 2025

                            Lead Product(s) : Amezosvatein

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II

                            Recipient : GC Biopharma

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Curevo Vaccine

                            U.S.A arrow
                            Neuroscience
                            Not Confirmed

                            Curevo Vaccine

                            U.S.A arrow
                            Neuroscience
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Amezosvatein

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II

                            Sponsor : Medicxi

                            Deal Size : $110.0 million

                            Deal Type : Series B Financing

                            DEALS_DEV arrow-down

                            Curevo Raises $110 Million to Advance Amezosvatein Shingles Vaccine

                            Details : The financing aims to advance the clinical development of company's mid-stage product CRV-101 (amezosvatein). It is being evaluated to prevent shingles.

                            Product Name : Undisclosed

                            Product Type : Vaccine

                            Upfront Cash : Undisclosed

                            March 17, 2025

                            Lead Product(s) : Amezosvatein

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II

                            Sponsor : Medicxi

                            Deal Size : $110.0 million

                            Deal Type : Series B Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Curevo Vaccine

                            U.S.A arrow
                            Neuroscience
                            Not Confirmed

                            Curevo Vaccine

                            U.S.A arrow
                            Neuroscience
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Amezosvatein

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Curevo Announces Positive Updated Phase 2 Data for Amezosvatein Shingles Vaccine

                            Details : CRV-101 (amezosvatein) uses an adjuvant targeting the TLR4 pathway to boost the immune response to the gE antigen. Currently being investigated for Shingles in 50 years and older.

                            Product Name : Undisclosed

                            Product Type : Vaccine

                            Upfront Cash : Inapplicable

                            January 12, 2025

                            Lead Product(s) : Amezosvatein

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Curevo Vaccine

                            U.S.A arrow
                            Neuroscience
                            Not Confirmed

                            Curevo Vaccine

                            U.S.A arrow
                            Neuroscience
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Amezosvatein

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Curevo Vaccine Reports Positive Phase 2 Results for Amezosvatein, a Shingles Vaccine

                            Details : CRV-101 (amezosvatein) is a non-mRNA, adjuvanted subunit vaccine, which is under phase 2 clinical development for the prevention of Herpes Zoster in adults aged 50 years and older.

                            Product Name : Undisclosed

                            Product Type : Vaccine

                            Upfront Cash : Inapplicable

                            January 07, 2024

                            Lead Product(s) : Amezosvatein

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Curevo Vaccine

                            U.S.A arrow
                            Neuroscience
                            Not Confirmed

                            Curevo Vaccine

                            U.S.A arrow
                            Neuroscience
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Amezosvatein

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II

                            Sponsor : Janus Henderson Investors

                            Deal Size : $26.0 million

                            Deal Type : Series A Financing

                            DEALS_DEV arrow-down

                            Curevo Vaccine Announces $26 Million Series A1 Financing to Support Clinical Development of Next-Generation Su...

                            Details : CRV-101 is a clinical-stage adjuvanted sub-unit vaccine under investigation for the prevention of shingles in older adults. Shingles is a painful blistering skin rash caused by a reactivation of the varicella zoster virus.

                            Product Name : Undisclosed

                            Product Type : Vaccine

                            Upfront Cash : Undisclosed

                            November 16, 2022

                            Lead Product(s) : Amezosvatein

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II

                            Sponsor : Janus Henderson Investors

                            Deal Size : $26.0 million

                            Deal Type : Series A Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Curevo Vaccine

                            U.S.A arrow
                            Neuroscience
                            Not Confirmed

                            Curevo Vaccine

                            U.S.A arrow
                            Neuroscience
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Amezosvatein

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Curevo Vaccine Announces Enrollment Complete in Phase 2b Trial of CRV-101 Vaccine Against Shingles

                            Details : CRV-101 is for the prevention of shingles in older adults. CRV-101 was specifically designed with a goal of producing an optimal immune response while using a smaller amount of adjuvant with the goal to create a vaccine with good tolerability and a simil...

                            Product Name : Undisclosed

                            Product Type : Vaccine

                            Upfront Cash : Inapplicable

                            September 15, 2022

                            Lead Product(s) : Amezosvatein

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Curevo Vaccine

                            U.S.A arrow
                            Neuroscience
                            Not Confirmed

                            Curevo Vaccine

                            U.S.A arrow
                            Neuroscience
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Amezosvatein

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II

                            Sponsor : Mogam Biotechnology Research Institute | Green Cross Lab Cell

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Safety and Immunogenicity of CRV-101 Vaccine for the Prevention of Herpes Zoster in Adults Aged 50 Years and O...

                            Details : Amezosvatein is a Vaccine drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Herpes Zoster.

                            Product Name : Undisclosed

                            Product Type : Vaccine

                            Upfront Cash : Inapplicable

                            March 31, 2022

                            Lead Product(s) : Amezosvatein

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II

                            Sponsor : Mogam Biotechnology Research Institute | Green Cross Lab Cell

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Curevo Vaccine

                            U.S.A arrow
                            Neuroscience
                            Not Confirmed

                            Curevo Vaccine

                            U.S.A arrow
                            Neuroscience
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Amezosvatein

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Curevo Vaccine Announces Robust Antibody Response Results of Phase I Clinical Trial of Investigational Vaccine...

                            Details : The administration of Curevo’s adjuvanted sub-unit Shingles investigational vaccine resulted in a robust antibody response against a key component (gE) of the shingles virus at 1 month after 2nd vaccination, and at one year.

                            Product Name : Undisclosed

                            Product Type : Vaccine

                            Upfront Cash : Inapplicable

                            September 15, 2020

                            Lead Product(s) : Amezosvatein

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Curevo Vaccine

                            U.S.A arrow
                            Neuroscience
                            Not Confirmed

                            Curevo Vaccine

                            U.S.A arrow
                            Neuroscience
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Amezosvatein

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase I

                            Sponsor : Access to Advanced Health Institute | Mogam Biotechnology Research Institute | Green Cross Lab Cell

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Safety, Tolerability, and Immunogenicity of CRV-101 in Healthy Adult Subjects

                            Details : Amezosvatein is a Vaccine drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Herpes Zoster.

                            Product Name : Undisclosed

                            Product Type : Vaccine

                            Upfront Cash : Inapplicable

                            January 29, 2019

                            Lead Product(s) : Amezosvatein

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase I

                            Sponsor : Access to Advanced Health Institute | Mogam Biotechnology Research Institute | Green Cross Lab Cell

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth